生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Azelnidipine is a calcium blocker that has been shown to have antioxidant effects in endothelial cells and cardiomyocytes. Azelnidipine inhibited TGF-β1- and Ang II-induced HSC (hepatic stellate cells) activation in vitro and attenuated CCl4- and TAA-induced liver fibrosis, and it accelerated regression of CCl4-induced liver fibrosis in mice[3]. Cultures of human mononuclear leukocytes collected from six healthy volunteers showed 100 nM of azelnidipine caused significant inhibition of formyl-methyonyl leucyl phenylalanine (fMLP)-induced production of IL-8. These results suggest that azelnidipine has anti-inflammatory effects independent of its anti-hypertensive action[4]. Moreover, beneficial effect of Azelnidipine in diabetic cardiomyopathy via altering intracellular Ca2+ handling proteins and preventing apoptosis by its antioxidant property[5]. Acute administration of azelnidipine could prevent a sudden drop of cardiac function after acute stress like IMO (immobilization stress: IMO). Azelnidipine might have a protective effect on stress-induced cardiac dysfunction like α and β adrenergic blockers[6]. Azelnidipine has potent antiatherosclerotic properties by inhibition of macrophage activation through Cav1.2[7]. |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT00134160 | Hypertension ... 展开 >>Cardiovascular Diseases 收起 << | Phase 4 | Completed | - | Japan ... 展开 >> Department of Cardiovascular Medicine Graduate School of Medical Science Kumamoto University 1-1-1 Honjyo, Kumamoto-City, Kumamoto, Japan, 860-8556 OSCAR-Study Data Center ShinjukuParkTower30FN, 3-7-1 Nishi-Shinjuku, Shinjuku-ku, Tokyo, Japan, 163-1030 收起 << |
NCT01819441 | Cerebral Small Vessel Diseases | Phase 4 | Unknown | December 2016 | China, Beijing ... 展开 >> Peking University First Hospital Recruiting Beijing, Beijing, China, 100034 Contact: Yining Huang ynhuang@sina.com 收起 << |
NCT00607035 | Hypertension | Phase 4 | Completed | - | Japan ... 展开 >> Jichi Medical University School of Medicine Tochigi, Japan 收起 << |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.72mL 0.34mL 0.17mL |
8.58mL 1.72mL 0.86mL |
17.16mL 3.43mL 1.72mL |
参考文献 |
---|